The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because they have dramatic efficacy. At the same time, safety concerns about biologics have been raised. In this paper, we focus on the safety profile of biologics for psoriasis. As of 2017, six biologics are available in Japan. Two tumor necrosis factor‐α inhibitors; infliximab and adalimumab, one anti‐interleukin ( IL )‐12/23p40 antibody; ustekinumab, and IL ‐17 inhibitors; secukinumab, ixekizumab and brodalumab. Secukinumab and ixekizumab are anti‐ IL ‐17A antibodies. Brodalumab is an anti‐ IL 17 RA antibody. In this review, we pick up topics which have drawn attention regarding the safety of biologics and discuss them with recent published work.
No takes yet. Share an insight, caveat, or question.
Kamata et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: